Walleye Capital
HQL

Walleye Capital’s abrdn Life Sciences Investors HQL Stock Holding History

Walleye Capital’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-49,963
Closed -$623K – 5186
2023
Q3 		$623K Sell
49,963
-3,257
-6% -$42.8K ﹤0.01% 2639
2023
Q2 		$721K Sell
53,220
-3,097
-5% -$42.7K ﹤0.01% 2141
2023
Q1 		$784K Buy
56,317
+8,362
+17% +$120K 0.01% 1342
2022
Q4 		$681K Buy
+47,955
New +$695K 0.01% 1242
2020
Q3 		– Sell
-13,704
Closed -$246K – 900
2020
Q2 		$246K Sell
13,704
-18,498
-57% -$317K 0.05% 380
2020
Q1 		$483K Buy
32,202
+7,600
+31% +$124K 0.11% 236
2019
Q4 		$429K Buy
+24,602
New +$404K 0.03% 752

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Cornerstone Advisors Asheville, North Carolina $2.72B AUM 22.17% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Walleye Capital's HQL Position: Q4 2023 in Review

Walleye Capital sold out of abrdn Life Sciences Investors (HQL) in Q4 2023, closing a stake of 49,963 shares — an estimated $623K sold.

Walleye Capital first reported a position in HQL in Q4 2019 and held it in 7 quarters. The position peaked at $784K in Q1 2023. 79 funds tracked by Wall St. Rank hold HQL as of Q4 2023.

  • Walleye Capital reported no remaining abrdn Life Sciences Investors position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 49,963 abrdn Life Sciences Investors shares in Q4 2023, an estimated $623K.
  • Walleye Capital first reported a position in abrdn Life Sciences Investors in Q4 2019 and held it in 7 quarters.
  • Walleye Capital's abrdn Life Sciences Investors position peaked at $784K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.